Musculoskeletal diseases such as rheumatoid arthritis are complex multifactorial disorders that are chronic in nature and debilitating for patients. A number of drug families are available to clinicians to manage these disorders but few tests exist to target these to the most responsive patients. As a consequence, drug failure and switching to drugs with alternate modes of action is common. In parallel, a limited number of laboratory tests are available which measure biological indicators or ‘biomarkers’ of disease activity, autoimmune status, or joint damage. There is a growing awareness that assimilating the fields of drug selection and diagnostic tests into ‘companion diagnostics’ could greatly advance disease management and improve outcomes for patients. This review aims to highlight: the current applications of biomarkers in rheumatology with particular focus on companion diagnostics; developments in the fields of proteomics, genomics, microbiomics, imaging and bioinformatics and how integration of these technologies into clinical practice could support therapeutic decisions.
- Companion Diagnostics
- Genomics ,
- Stratified Medicine
Gibson, D., Bustard, M., McGeough, C., Murray, H. A., Crockard, M. A., Mc Dowell, A., ... Bjourson, AJ. (2015). Current and future trends in biomarker discovery and development of companion diagnostics for arthritis. Expert Review of Molecular Diagnostics, 15(2). https://doi.org/10.1586/14737159.2015.969244